No Data
No Data
AstraZeneca's Enhertu Application Accepted by FDA With Priority Review
ENHERTU (Fam-trastuzumab Deruxtecan-nxki) Granted Priority Review in the US for Patients With HER2-low or HER2-ultralow Metastatic Breast Cancer Who Have Received at Least One Line of Endocrine Therapy
AstraZeneca, Daiichi Sankyo's Breast Cancer Treatment Enhertu Accepted for US Priority Review
ADR Japanese stock rankings ~ Yucho Bank and others are almost entirely down, Chicago down 2400 yen compared to Osaka, at 37,450 yen.
Japanese stocks of American Depositary Receipts (ADRs) fell compared to the Tokyo Stock Exchange (1 dollar equivalent to 142.21 yen), with Yucho Bank <7182>, Disco <6146>, Advantest <6857>, Renesas <6723>, Hitachi Ltd <6501>, Shin-Etsu Chemical Co. <4063>, Murata Manufacturing Co. <6981>, etc. all declining, resulting in almost across-the-board declines. The Chicago Nikkei 225 futures settlement price was 2,400 yen lower at 37,450 yen compared to Osaka's daytime, etc. The U.S. stock market showed mixed performance, with the Dow Jones average down 137.89 dollars.
Top Quant-rated Japan Stocks as BoJ Will Likely Stop Rate Hikes in 2024 – Jefferies
Daily closing at a high price due to expectations for the LDP leadership election
The Nikkei average continued to significantly rise. It closed at 39,829.56 yen, up 903.93 yen (with a volume estimate of 2.240 million shares) at the end of trading. Buying took the lead as major stock price indices rose in the U.S. market the previous day. The Nikkei average started by breaking through the psychological milestone of 39,000 yen. Subsequently, there were moments where the upward momentum was reduced due to the anticipation of wanting to assess the results of the LDP presidential election. However, following the first round of voting in the LDP presidential election, Fumio Kishida, former Secretary-General, and Sanae Takaichi, Minister of Economy, Trade and Industry, advanced to the runoff, and the Nikkei
No Data
No Data
han so heee : come 60
han so heee :